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Abstract 
Review on NFE2L2, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: NRF2 
HGNC (Hugo): NFE2L2 
Location: 2q31.2 
Note 
The transcription factor Nrf2, encoded by the 
NFE2L2 gene, is the mediator of a cellular 
antioxidant response. Nrf2 belongs to the cap'n'collar 
(cnc) family of transcription factors. 
DNA/RNA 
Description 
The NFE2L2 gene is approximately 34.8 kb in size. 
The mouse homologue of the NFE2L2 gene is a self- 
and hetero-inducible gene; its promoter region 
contains two ARE/EpRE (antioxidant or electrophile 
response element) sequences at -492 bp and -754 bp, 
through which it is induced by Nrf2. In addition, its 
regulatory region contains three XRE (xenobiotic 
response element) sequences at -712 bp, +755 bp and 
+850 bp. ARE and XRE sequences are implicated in 
the inducible upregulation of the gene¡s 
transcription. A kB2 region for NF-κB binding has 
been detected at +270 bp; proinflammatory stimuli 
can induce human NFE2L2 transcription via this 
element. On the other hand, five CpG sequences in 
the promoter region of NFE2L2 allow 
hypermethylation and repression of gene expression 
(Kwak et al., 2002; Hayes and Dinkova-Kostova, 
2014). 
NFE2L2 gene - transcript variants. NFE2L2 gene located 
on chromosome 2. Multiple transcript variants (TV) 
encoding different isoforms have been found for this gene. 
The transcript variants referenced more often in the 
literature are NM_006164.4 (TV 1), NM_001145412.2 (TV 
2) and NM_001145413.2 (TV 3).
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Structural and functional domains of Nrf2. A. Structural features of the human Nrf2 protein that dictate its activity. The 
interaction with Keap1 is mediated by the Neh2 (Nrf2 extended homology 2) domain of Nrf2. B. Nuclear localisation signals 
(NLS) and nuclear export signals (NES) have been detected in the Nrf2 sequence. The NESTA motif is the only one shown to be 
directly redox-sensitive. C. Specific cysteine residues have been characterised as reactive, meaning that they are sensitive to 
oxidation. Oxidative stress also activates intracellular kinases such as PKC and Fyn which in turn phosphorylate Nrf2 (on Ser40 




NM_006164.4 (TV 1) comprises 5 coding exons and 
is approximately 2.8 kb in size; this transcript 
encodes the longest protein isoform. 
NM_001145412.2 (TV 2) and NM_001145413.2 
(TV 3) comprise 4 coding exons each and are 
approximately 2.7 kb and 2.4 kb in size, respectively. 
MiRNAs 
miRNA3128 is a non-coding RNA that is the 
transcript product of a region in the first intron of 
NFE2L2 (chr. 2: 177255945-177256010, 
complement). It is not known whether it has a role in 
the regulation of NFE2L2 expression. Micro RNAs 
species reported to suppress NFE2L2 expression 
include miR-27a, miR-28, miR-34a, miR-93, miR-
142-5p, miR-144, and miR-153 (Filipowicz et al., 




Name: Nuclear factor erythroid 2-related factor 2. 
Short: NF-E2-related factor 2, NFE2-related factor 
2. 
Alternatives names: Nuclear factor, erythroid 
derived 2, like 2, NF-E2 p45-related Factor-2. 
Nrf2, the nuclear factor erythroid 2 (NF-E2)-related 
transcription factor 2, was first described in 1994 by 
Moi et al. by screening for factors that could bind to 
a NFE2-binding DNA sequence. The human Nrf2 
protein NP_006155.2 (encoded by TV 1) is  
67.8 kDa in weight and consists of 605 amino acids; 
NP_001138884.1 (encoded by TV2) is 66.1 kDa in 
weight and consists of 589 amino acids; and 
NP_001138885.1 (encoded by TV3) is 65.4 kDa in 
size and consists of 582 amino acids. 
Nrf2 has been characterized as a modulator protein 
and is the core of the Nrf2 antioxidant 
system/pathway. Other main components of the 
pathway are Keap1, the negative regulator of Nrf2, 
and small Maf proteins which serve as cofactors for 
Nrf2 binding to regulatory DNA sequences of ARE-
regulated genes (Moi et al., 1994; Li and Kong, 
2009). 
Description 
Nrf2 binds to ARE sites of antioxidant genes as a 
heterodimer. Specifically, Nrf2 heterodimerizes with 
small Maf proteins (which are themselves devoid of 
transcription activating domains) to induce the 
transcription of ARE-regulated genes. Other binding 
partners include members of the AP-1 transcription 
factor family like Jun and Fos. In contrast, 
homodimers or heterodimers of the different small 
Maf proteins, and heterodimers of Bach proteins 
with small Maf proteins on AREs, have been 
characterised as negative regulators of Nrf2 
signalling pathway that compete with Nrf2 for 
binding to AREs. The co-factor CBP/p300 is 
indispensable for transcription activation by Nrf2 
and localizes to ARE-binding sites in association 
with Nrf2-small Maf heterodimers 
(Dhakshinamoorthy et al., 2005; Ishikawa et al., 
2005; Li et al., 2008; Hirotsu et al., 2012). 
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Crystal structures of the Nrf2-binding domain of Keap1 (Keap1 DC/Kelch domain) in complex with peptides derived 





Nrf2 is considered to be ubiquitously expressed, as it 
has been shown to be expressed in various cell types 
(including lung, liver, kidney, stomach, small 
intestine, neurons, astrocytes, etc) and it has been 
considered a multi-organ protector that enhances the 
cellular resistance to potential harmful insults that 
occur during cells' normal activities and during 
environmental exposures. Morevoer, Nrf2 has been 
found to be overexpressed in various human cancers 
(Yoo et al., 2012; Lee and Surh, 2005). 
Localisation 
Nrf2 can be detected both in the cytoplasm and in the 
nucleus; the Keap1-mediated degradation of Nrf2 
occurs in the cytoplasm. In addition, one of the 
proposed models for the Keap1-Nrf2 interaction 
suggests that a Keap1 dimer can bind one Nrf2 
molecule and one PGAM5 molecule. PGAM5 
possesses a N-terminal membrane targeting signal, 
through which the Nrf2-Keap1-PGAM complex is 
tethered to the cytosolic surface of the outer 
mitochondrial membrane. As a result, Nrf2 can be 
also localised in the perimitochondrial region 
(Sykiotis and Bohmann, 2010). 
Function 
The Nrf2/Keap1 pathway is a major mediator of 
cytoprotective responses to oxidative and 
electrophilic stress. Nrf2 responds to oxidative stress 
by inducing the transcriptional upregulation of a 
broad range of cytoprotective genes whose 
promoters contain Antioxidant Response Element 
(ARE) sequences. Specifically, Nrf2 translocates to 
the nucleus, heterodimerizes with small Maf proteins 
and binds to ARE sequences to induce gene 
transcription. When redox balance is restored, Nrf2 
activity is repressed via export from the nucleus back 
into the cytoplasm and degradation via a Cullin - 
RING ligase 3 - Keap1 complex (CRLkeap1 
complex), and by other mechanisms (Zhang, 2006). 
 
Oxidative stress and the antioxidant 
transcriptional response mediated by Nrf2  
Cells and tissues are constantly exposed to various 
oxidative substances and electrophilic chemicals, 
including reactive oxygen species (ROS) and 
reactive nitrogen species (RNS), derived from both 
endogenous and exogenous sources. To adapt to the 
oxidative environment, cells have developed 
elaborate and highly efficient antioxidant 
machineries. When pro-oxidant and electrophilic 
challenges overwhelm the cell's antioxidant and 
detoxification proteins, cells experience oxidative 
stress. Oxidative stress conditions can cause damage 
to cellular structures, including lipids, proteins, and 
nucleic acids. Among other injuries, this can lead to 
mutations and epigenetic perturbations by damaging 
DNA and proteins that modify chromatin. Thus, 
oxidative stress can be a causative or exacerbating 
factor in a range of diseases, including, for example, 
respiratory and metabolic disorders, 
neurodegenerative diseases, and cancer. 
In order to maintain homeostasis in the face of 
oxidative insults, cells possess signalling pathways 
that can sense oxidative stress and launch adaptive 
responses. Multiple ways of managing the 
intracellular oxidative load have been identified over 
the last two decades; among them, it has been 
recognized that gene transcription can be regulated 
by redox reactions. Prominent among the redox-
sensitive pathways of gene activation is the Nrf2 
system. The core of this pathway comprises the 
transcription factor Nrf2 and its negative regulator 
Keap1. In addition, small Maf proteins serve as 
dimerization partners of Nrf2 to facilitate its binding 
to DNA on special sequences termed antioxidant 
response elements (AREs) or  
electrophile response elements (EpREs) in the 
regulatory regions of the many Nrf2-regulated 
genes, including the genes encoding glutamate 
cysteine ligase catalytic subunit (GCLC), heme 
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oxygenase-1 (HO-1), NADP(H) quinone 
oxidoreductase-1 (NQO1), microsomal glutathione-
S-transferases such as MGST1 and MGST2, and 
multi-drug resistance-associated proteins such as 
ATP-binding cassette, subfamily C (CFTR/MRP), 
member 1 (ABCC1) (Magesh et al., 2012; Hayes and 
Dinkova-Kostova, 2014). 
Activity and regulation of Nrf2 
The Nrf2 pathway responds to oxidative stress by 
inducing the transcriptional upregulation of a broad 
range of cytoprotective genes.  
The Nrf2 system responds to both endogenous 
reactive molecules, such as reactive oxygen species 
(ROS) and reactive nitrogen species (RNS), and to  
 
exogenous substances.  
The sensing mechanisms comprise oxidation or 
alkylation of critical Keap1 cysteine residues 
(including Cys151, Cys273 and Cys288), and 
phosphorylation of Nrf2 on amino acids Ser40 and 
Tyr568 (Zhang and Hannink, 2003; Yamamoto et 
al., 2008; Magesh et al., 2012). 
When redox homeostasis is restored, Nrf2 activity is 
repressed via export from the nucleus back into the 
cytoplasm and degradation via a Cullin-RING ligase 
3 - Keap1 complex (CRLkeap1 complex). Nrf2 can 
also trigger a feedback loop of increased expression 
of ARE-dependent genes including Keap1 and Cul3, 
which then promote Nrf2 degradation and thus 
participate in resetting Nrf2 activity at its basal level 
(Rachakonda et al., 2008; Eggler et al., 2009; Baird 
and Dinkova-Kostova, 2011). 
 
 
A. Keap1 binds Nrf2 and inhibits its transcriptional activity. The depicted "hinge-and-latch" model proposes a 2:1 Keap1:Nrf2 
molecular stoichiometry. B. At the basal cellular state (low oxidative burden), Nrf2 undergoes Keap1-Cul3-mediated poly-
ubiquitination and proteasomal degradation. 
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Two mechanistic models for the Nrf2-Keap1 interaction. Adapted from Sykiotis and Bohmann, 2010. 
 
 
Activation of Nrf2 pathway 
A. Transcriptional induction of the NFE2L2 gene 
A1. Nrf2 autoregulation 
It has been shown that the promoter of the mouse 
orthologue of the NFE2L2 gene includes two 
antioxidant response element-like sequences (ARE-
L1 and ARE-L2), which are located at -492 bp and -
754 bp from the transcription start site, respectively.  
It has been proposed that under stress conditions 
newly translated Nrf2 protein escapes Keap1-
mediated degradation and binds to the ARE-L1 and 
ARE-L2 sequences to induce NFE2L2 gene 
transcription in a feed-forward manner (Shin et al., 
2007; Hayes and Dinkova-Kostova, 2014). 
A2. NFE2L2 transcription induced by the 
oncoproteins K-Ras and B-Raf 
It has been demonstrated that oncogene-directed 
increased expression of the NFE2L2 gene can be an 
alternative mechanism of Nrf2 activation. K-Ras and 
B-Raf, which operate in the mitogen-activated 
protein kinase (MAPK) pathway, have been shown 
to increase NFE2L2 transcription via activation of 
Jun or/and Myc. It has been proposed that via this 
mechanism oncogenic signaling may modulate 
redox homeostasis during tumirogenesis (DeNicola 
et al., 2011). 
A3. Cross-talk of Nrf2 with the NF-κB and AhR 
signaling pathways 
In general, the effects of the intracellular events 
induced by Nrf2 activation lead to NF-κB 
suppression, and vice versa; thus, overall, Nrf2 
signaling antagonises NF-κB signaling. 
Nevertheless, in acute myeloid leukemia it has been 
reported that Nrf2 is upregulated by NF-κB-
mediated transactivation of the NFE2L2 gene by 
direct binding of NF-κB to the NFE2L2 promoter 
(Rushworth et al., 2012). 
The AhR/ARNT complex (aryl hydrocarbon 
receptor / AhR nuclear translocator) regulates gene 
transcription in response to xenobiotics, such as 
polycyclic aromatic hydrocarbons, via binding to 
xenobiotic response elements (XREs). Three XRE-
like elements have been identified in the mouse 
Nfe2l2 promoter; via these elements, the AhR/XRE 
pathway can control Nrf2/ARE signaling (Miao et 
al., 2005). 
A4. BRCA1 / ARNT-mediated induction of 
NFE2L2 gene transcription 
The transcription factor BRCA1 (breast cancer 1, 
early onset) has been reported to increase the 
transcription of the NFE2L2 gene. As BRCA1 has 
the ability to interact with ARNT, it is possible that 
BRCA1 induces Nrf2 expression in an ARNT-
dependent manner (Kang et al., 2006). 
B. Post-translational activation of Nrf2 






Atlas Genet Cytogenet Oncol Haematol. 2015; 19(8) 508 
 
B1. The "hinge and latch" and "quaternary" 
models 
At basal conditions (meaning the absence of 
oxidative stress) the NFE2L2 gene is constantly 
transcribed and Nrf2 protein is constantly 
synthesized, but Nrf2 protein abundance and activity 
are maintained at low levels due to the negative 
regulation of Nrf2 by Keap1 through the CRLkeap1 
complex. 
The "hinge and latch" model has been proposed as a 
mechanistic model that accounts for the interaction 
between Nrf2 and Keap1 and provides as structural 
basis for the Keap1-dependent polyubiquitination 
and degradation of Nrf2. This model posits an 
interaction of one Nrf2 molecule with a Keap1 
homodimer, in which the high affinity binding of the 
ETGE motif of the Neh2 domain of Nrf2 functions 
as a "hinge" to fix Nrf2 to one of two Keap1 
molecules, whereas the low affinity binding of the 
DLG motif of the Neh2 domain of Nrf2 functions as 
a "latch" to lock down the Neh2 domain to the other 
Keap1 molecule of the homodimer. The fixation of 
the Neh2 domain between the two Keap1 molecules 
thus facilitates its ubiquitination and the subsequent 
degradation of Nrf2 by the 26S proteasome. A 
competing structural model is the "quaternary 
complex" model, which proposes that a Keap1 dimer 
binds two molecules of substrate through high-
affinity interactions with ETGE motifs. Specifically, 
a Keap1 dimer can bind two Nrf2 molecules, or one 
Nrf2 molecule and one PGAM5 molecule. PGAM5 
possesses an N-terminal membrane targeting signal 
through which the Nrf2-Keap1-PGAM complex is 
tethered to the cytosolic surface of the outer 
mitochondrial membrane (Tong et al., 2006; Sykiotis 
and Bohmann, 2010; Kansanen et al., 2012), 
potentially to allow Nrf2 to be activated in response 
to mitochondrial leakage of ROS. 
Under conditions of oxidative stress, it is believed 
that the oxidative modification of certain cysteine 
residues of Keap1 leads to conformational changes 
of the Keap1 dimer. In the "hinge and latch" model, 
this results in dissociation of the DLG motif from 
Keap1, wuch that Nrf2 cannot be properly presented 
for ubiquitination by the CRLkeap1 complex and thus 
escapes proteosomal degradation. The stabilized 
Nrf2 accumulates in the nucleus where it 
heterodimerizes with small Maf proteins and binds 
to AREs, leading to transcription of ARE-dependent 
cytoprotective genes (reviewed in Sykiotis and 
Bohmann, 2010; Hayes and Dinkova-Kostova, 
2014). 
B2. Phosphorylation of Nrf2 by PKC 
Several protein kinases, including protein kinase C 
(PKC), have been implicated in the upstream 
regulation of Nrf2 pathway. Specifically, 
phosphorylation of Nrf2 by PKC induces nuclear 
translocation of this transcription factor and 
activation of the ARE in response to oxidative stress. 
Furthermore, it has been found that PKC 
phosphorylates Nrf2 at Ser-40 facilitating its release 
from Keap1-mediated inhibition (Wakabayashi et 
al., 2010; Stepkowski and Kruszewski, 2011). 
B3. The redox signaling "model of two Nrf2 
pools" 
Multiple NLS/NES (Nuclear localisation signal/ 
nuclear export signal) motifs have been identified in 
the Nrf2 sequence. These include three NLS motifs 
(bNLS, NLSN and NLSc) and two NES motifs 
(NESTA and NESZIP) but only the NESTA motif has 
been found to be redox-sensitive. Specifically, the 
NESTA motif has been shown to display a graded 
response to oxidative stress, implying that it can not 
only sense the presence of reactive oxidative species, 
but it also has the ability to transmit the oxidative 
stress "intensity" to the nucleus in order to up-
regulate the transcription of ARE-genes accordingly. 
Based on these observations, Nrf2 has been proposed 
as a direct redox-sensor. Specifically, under basal 
condition a dynamic balance can be observed as the 
combined nuclear exporting forces of NESTA and 
NESZIP counteract the combined nuclear importing 
force of the bNLS, NLSN and NLSc leading to a 
whole-cell distribution of Nrf2. However, under 
oxidative stress the NESTA is functionally disabled, 
and the driving force of NLSs becomes dominant 
and favors the nuclear localization of Nrf2. 
The NLS/NES motifs and their role in activation of 
Nrf2 have led to the hypothesis for Keap1-
independent Nrf2 signaling. Nevertheless, this 
model does not exclude Keap1 involvement in redox 
signaling. Consequently, a new model has been 
proposed that encompasses both Keap1-dependent 
and Keap1-independent Nrf2 signaling. This model 
proposes that in cells there may exist a free-floating 
pool of Nrf2 (fNrf2) and a Keap1-bound pool of Nrf2 
(kNrf2). Under homeostatic conditions there is an 
equilibrium between synthesis and degradation of 
Nrf2, such that the fNrf2 pool remains small. But 
when cells are exposed to oxidative stress, the Nrf2-
binding capacity of Keap1 is diminished and the 
fNrf2 pool is enlarged. As the NESTA of the fNrf2 
redox-sensitive pool is disabled by the stress, nuclear 
localization of Nrf2 is favored (Li and Kong, 2009). 
B4. Competitors of Nrf2 for binding to Keap1 
It has been demonstrated that the ability of Keap1 to 
repress Nrf2 can be modulated by proteins that also 
possess ETGE motifs and thereby compete with 
Nrf2 for the same binding site in Keap1. For 
example, dipeptidyl-peptidase 3 (DPP3), IκB kinase 
β (IKKβ), partner and localizer of BRCA2 (PALB2), 
phosphoglycerate mutase 5 (PGAM5) and Wilms 
tumor gene on X chromosome (WTX) contain 
ETGE motifs that enable them to bind Keap1 and act 
as competitors of Nrf2 (Hayes and Dinkova-
Kostova, 2014). 
B5. mTOR signaling and p62-dependent 
degradation of Keap1 
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There is also cross-talk between Nrf2-Keap1 
signaling and autophagy. It has been shown that in 
normal cells this interaction serves as a host defence 
mechanism leading to expression of antioxidant 
enzymes as well as elimination of cytotoxic 
products. Keap1 can bind the autophagy cargo 
receptor p62, which contains an STGE motif similar 
to the ETGE motif of Nrf2. Following 
phosphorylation of Ser 351 within its STGE motif by 
the mammalian target of rapamycin complex 
(mTORC1), p62 becomes a potent inhibitor of 
Keap1. p62 is phosphorylated by mTORC1 in the 
presence of ubiquitinated autophagic cargos, which 
can occur under oxidative conditions; this in turn 
favors the binding of Keap1 to the phosphorylated 
STGE motifs. As a result, Keap1 is sequestrated in 
autophagy cargos in a p62-dependent manner, 
allowing Nrf2 to be stabilized and to accumulate in 
the nucleus to induce cytoprotective enzymes 
(Komatsu et al., 2010; Ichimura et al., 2013; 
Lamming and Sabatini, 2013). 
B6. Cross-talk between p53/p21 and the Nrf2 
pathway 
The p53 tumor suppressor protein regulates several 
intracellular procedures including gene transcription 
and induction of apoptosis. It has been demonstrated 
that p53 is implicated in the regulation of the Nrf2-
mediated oxidative response in a dual manner: under 
low or mild levels of oxidative stress, p53 promotes 
the stabilization of Nrf2 and its subsequent nuclear 
accumulation through the transcriptional activation 
of p21, and as a result reduces the oxidative burden 
to promote cell survival. p21 stabilizes Nrf2 due to 
the existence of a KRR motif within the p21 
sequence which interacts with the DLG motif of 
Nrf2 inhibiting its binding to Keap1. On the other 
hand, under conditions of high or sustained levels of 
oxidative stress, Nrf2-mediated cell survival is 
suppressed, and high activity levels of p53 induce 
apoptosis to prevent tumorigenesis (Chen et al., 
2009; Chen W et al., 2012). 
B7. Competitive binding of BRCA1 to Nrf2 
The ability of Keap1 to repress Nrf2 can be 
diminished by the competitive binding of breast 
cancer protein BRAC1, thereby preventing Keap1 
from simultaneously binding to the ETGE motif of 
Nrf2 (Gorrini et al., 2013). 
B8. Acetylation of Nrf2 by p300/CBP  
It has been found that acetylation of the Neh1 
domain of Nrf2 can increase the binding affinity of 
Nrf2-Maf heterodimers for ARE sequences. 
p300/CBP acetylates lysine residues of the Neh1 
domain and enhances the interaction between Nrf2 
and ARE sequence of antioxidant genes promoter 
resulting in induction of the respective genes' 
transcription (Sun et al., 2009). 
Other mechanistic models which have been 
proposed for Nrf2 stabilization and activation 
include the oxidation-induced dissociation of the 
CRLkeap1complex, and the nucleocytoplasmic 
shuttling of Keap1 (Rachakonda et al., 2008; Eggler 
et al., 2009; Baird and Dinkova-Kostova, 2011). 
Repression of Nrf2 signaling 
A. Transcriptional repression of the NFE2L2 
gene 
A CpG island has been identified in the 5' flanking 
region of the NFE2L2 gene that extends to position 
-1175. The first 5 CpGs in this CpG island are found 
to be hypermethylated in prostate cancer samples 
and prostate cancer cell lines compared to normal 
prostate issues and cells. This hypermethylation 
leads to repression of NFE2L2 gene expression, 
potentially favouring tumorigenesis (Yu et al., 
2010). 
B. Post-transcriptional repression of Nrf2 
At the post-transcriptional level, various micro 
RNAs (miRNAs) have been identified to interact 
with the Nrf2 mRNA resulting in repression of Nrf2 
expression, including miR-27a, miR-28, miR-93, 
miR-142-5p, miR144 and miR-153 (Hayes and 
Dinkova-Kostova, 2014). 
C. Post-translational repression of Nrf2 
C1. CRLkeap1 complex-mediated degradation of 
Nrf2 
As mentioned, the CRLkeap1 complex is responsible 
for the ubiquitination and 26S degradation of Nrf2 
under normal conditions. Keap1 acts as an adaptor 
protein to mediate the interaction between Nrf2 and 
the Cul3 E3-ligase enyme, resulting in ubiquitination 
of lysines residues of the region located between the 
ETGE and DLG motifs in the Neh2 domain. 
Thereafter, ubiquitinated Nrf2 undergoes 
degradation by the 26S proteosome. It has been 
reported that the Nedd8 molecule serves as a factor 
of stabilization of the CRLkeap1 complex, and that the 
removal of Nedd8 by the CSN signalosome causes 
disruption of the complex and inhibition of Nrf2 
ubiquitination. CAND1 is a mediator protein that can 
also block the degradation process of Nrf2 
(Villeneuve et al., 2010). 
C2. Crm1-dependent nuclear export and β-
TrCP-dependent degradation of Nrf2 
Nrf2 degradation by Keap1 is mediated by 
interaction via the Nrf2 Neh2 ETGE and DLG 
motifs. Nevertheless, in Nrf2 proteins mutant for the 
ETGE and DLG motifs, it has been observed that the 
Neh6 domain accounts for some of the residual 
instability of Nrf2 in a Keap1-independent way. 
Specifically, it has been shown that the DSGIS and 
DSAPGS motifs located within the Neh6 domain 
serve as binding sites through which Nrf2 binds with 
β-TrCP. β-TrCP has the ability to target Nrf2 for 
ubiquitination and degradation through a Skp1-
Cul1-Rbx1/ Roc1 ubiquitin ligase complex; in vitro 
experiments with fibroblasts where β-TrCP is 
knocked down have shown increased Nrf2 protein 
levels. 
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This mechanism participates in the post-induction 
regulation of Nrf2 activity. The serine/threonine 
kinase GSK-3 controls the activity of the nuclear 
kinase Fyn which in turn phosphorylates Tyr568 of 
Nrf2 and promotes its Crm1 (exportin)-mediated 
export from the nucleus. GSK-3-mediated Fyn 
phosphorylation also causes an increase of the 
DSGIS degron activity in the Neh6 domain. The 
latter results in β-TrCP binding to the Neh6 domain 
of Nrf2 and consequently in β-TrCP-mediated Nrf2 
degradation (Jain and Jaiswal, 2007; Chowdhry et 
al., 2013). 
C3. Repression of Nrf2 by CRIF1, SIAH2 and 
RNF4 
The CR6-interacting factor 1 (CRIF1) can promote 
the ubiquitination of Nrf2 through its interaction 
with both the N-terminal Neh2 and C-terminal Neh3 
domains of Nrf2. The physiological circumstances 
when CRIF1 represses Nrf2 activity remain obscure. 
During hypoxia, it has been observed that SIAH2 
can lead to Nrf2 ubiquitination in a Neh2-
independent manner. Further work is required to 
elucidate the basis of interaction between SIAH2 and 
Nrf2 and the conditions that regulate it. 
It has been reported that small ubiquitin-like 
modifiers 1 and 2 (SUMO-1, SUMO-2) 
polysumoylate Nrf2 in promyelocytic leukemia  
 
nuclear bodies.  
The polysumoylated Nrf2 (pNrf2) translocates into 
the nucleus where SUMO-specific RING finger 
protein 4 (RNF4) ubiquitinates the pNrf2 leading it 
to degradation within the nucleus (Hayes and 
Dinkova-Kostova, 2014). 
C4. Negative feedback loops regulating Nrf2 
In vitro experiments have shown that antioxidant 
treatment can induce the expression of Keap1, 
suggesting a possible role of Nrf2 in the regulation 
of Keap1 expression.  
Keap1 has three ARE sequences within its promoter, 
of which one ARE on the reverse strand (position -
46) has been demonstrated to be functional in 
facilitating KEAP1 gene transcription. Thus, it has 
been suggested that Nrf2 can control its own 
degradation by binding to the Keap1 ARE(-46) and 
thereby inducing KEAP1 transcription.  
In other words, there exists an autoregulatory loop in 
which Nrf2 controls Keap1 at the transcriptional 
level and Keap1 regulates Nrf2 at the post-
translational level (Lee et al., 2007). 
Similarly, it has been observed that Nrf2 regulates 
the expression of the Cul3 and Rbx1 genes.  
The Cul3 and Rbx1 proteins are constituents of the 
CRLkeap1 complex which is responsible for the 
ubiquitination of Nrf2.  
Specifically, it has been found that both the Cul3 
gene promoter and the Rbx1 gene promoter contain 
one functional ARE, and that Nrf2 acts in an 
autoregulatory way by binding to these AREs to 
regulate the expression of the Cul3 and Rbx1 genes 
(Kaspar and Jaiswal, 2010). 
 
 
Schematic overview of the main steps in the regulation of the Keap1-Nrf2 antioxidant response pathway. Adapted from 
Sykiotis and Bohmann, 2010. 
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A phylogenetic tree of the Cnc and Bach transcription factors. A multiple species alignment was constructed with ClustalW 
(www.ebi.ac.uk/clustalw), and a phylogenetic tree was generated with the Jalview applet. The tree was based on the largest gap-
free block of aligned sequences, which contained the DNA binding domains of the Cnc and Bach factors. Accession numbers: 
mouse p45 NFE2, NP_032711.2; mouse Nrf1, NP_032712.2; mouse Nrf2, NP_035032.1; mouse Nrf3, NP_035033.1; mouse 
Bach1, NP_031546.1; mouse Bach2, NP_001103131.1; Drosophila CncC, NP_732833.1; C. elegans SKN-1, NP_741404.1 
(Sykiotis and Bohmann, 2010). 
 
 
In addition, there is evidence that Nrf2 is implicated 
in the expression of genes encoding 26S proteasome 
subunits, presumably in order to increase the 
proteasome-dependent removal of oxidatively 
damaged proteins. Therefore, it has been proposed 
that Nrf2 may regulate this negative autoregulatory 
feedback loop via the proteasome to restore its levels 
to the basal state after the removal of oxidative 
stimuli (Chapple et al., 2012). 
Furthermore, it is known that Bach1 competes with 
Nrf2 for binding to the ARE-sequence of Nrf2-
regulated genes. It has been demonstrated that Bach1 
transcript variant 2 has an intronic ARE sequence 
(position +1411) and can be a transcriptional target 
gene of Nrf2 (negative autoregulatory feedback 
mechanism) (Jyrkkänen et al., 2011). 
Finally, it has been recently discovered in cancer cell 
lines that retinoid X receptor α (RXRα) serves as an 
inhibitor of Nrf2 that regulates Nrf2 activity through 
a direct interaction with Neh7 domain, where a 
RXRα-binding site has been mapped. As the 
activation of Nrf2 results in upregulation of RXRα, 
this can form another negative feedback loop for 
Nrf2 regulation (Wang et al., 2013). 
Homology 
Nrf2 belongs to a family of basic leucine zipper 
(bZip) transcription factors called cap'n'collar (cnc) 
proteins. Cnc proteins are defined by the presence of 
a conserved 43-amino acid cnc domain located N-
terminally to the DNA-binding domain (bZip 
structure) and are conserved in invertebrates and 
vertebrates but not present in plants or fungi. The 
best studied cnc proteins are the C. elegans SKN-1 
(Skin family member 1), the D. melanogaster Cnc 
(isoforms B and C), and four vertebrate counterparts: 
the p45 NFE2 (nuclear factor erythroid-derived 2) 
and the NFE2-related factors Nrf1, Nrf2 and Nrf3 
("the Nrfs"). In addition, the related transcription 
factors Bach1 and Bach2 are characterised by the 
additional presence of a BTB protein interaction 
domain (Sykiotis and Bohmann, 2010). 
Although most Cnc factors are transcriptional 
activators, Bach1 and Bach2 function mainly 
(through not exclusively) as transcriptional 
repressors (figure below). Some of the Cnc proteins 
have important roles in development; for example, 
CncB is required for the development of head 
segments in D. melanogaster. Other family members 
(including Nrf2) are dispensable for development 
but rather contribute to the maintenance of cellular 
homeostasis in response to endogenous or 
exogenous stressors. In particular, the three Nrfs 
have broad and partly overlapping expression 
patterns and function as stress-activated 
transcription factors (Sykiotis and Bohmann, 2010). 
Mutations 
Somatic 
Somatic mutations of the NFE2L2 gene have been 
detected in cancers. Mainly missense mutations and 
in frame insertions/deletions of NFE2L2 localised in 
the DLG and ETGE motifs of the Neh2 domain 
cause modifications in Nrf2 protein that lead to 
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impaired interaction of Nrf2 with Keap1, and 
thereby to constitutive Nrf2 activation.  
Thus, the Nrf2 pathway is currently believed to have 
a role not only in cancer prevention via 
detoxification and maintenance of cellular 
homeostasis, but also in the cell growth and survival 
of malignant or premalignant cells. NFE2L2 
mutations have been identified in oesophageal 
squamous cell carcinoma (8/70, 11.4%; 6/32, 
18.8%), skin cancer (1/17, 6.3%; 1/22, 4.5%), non-
small cell lung carcinoma (NSCLC, 6.9-10.7%), 
head and neck carcinoma (HN, 13-25%), cervical 
cancer (1/18, 5.6%) and papillary renal cell 
carcinoma (2 cases).  
Interestingly, lung cancer, and particularly non-
small cell lung cancer, has been investigated for 
NFE2L2 mutations in various patient populations, 
and in all studies the presence of NFE2L2 mutations 
was positively correlated with smoking history. In 
addition, it has been observed that the frequency of 
NFE2L2 gene mutations is higher in lung squamous 
cell carcinoma than in lung adenocarcinoma (Shibata 
et al., 2008a; Kim et al., 2010; Solis et al., 2010; 
Shibata et al., 2011; Hu et al., 2012; Gantildeán-
Gómez et al., 2013; Ooi et al., 2013).  
NFE2L2 polymorphisms  
Specific polymorphisms associated with disease 
risk*  
Respiratory disorders 
Heterozygosity (T/G) for rs6721961 (T/C/G) has 
been associated with increased risk of acute lung 
injury (ALI) in patients with major trauma in 
Caucasian/African-American and Japanese 
populations. Paradoxically, in a Japanese cohort, the 
haplotype (rs2001350T/rs6726395A/ 
rs1962142A/rs2364722A/rs6721961T) containing 
the homozygous SNP rs6721961 TT has been 
correlated with lower annual decline in forced 
expiratory volume in one second (FEV1), a measure 
of pulmonary function. In contrast, the rs6726395 G 
allele showed association with higher annual decline 
of FEV1 induced by cigarette smoking in Japanese.  
Furthermore, a haplotype containing rs35652124 C, 
rs6706649 C, rs6721961 G and GGC4 (a repeat 
polymorphism) has been proposed as a predictor 
factor of increased respiratory failure development 
in German patients with chronic obstructive 
pulmonary disease (COPD). A further study in a 
Netherlands population showed correlations 
between rs1806649 C and reduced COPD mortality, 
and between the rs2364723 CC and reduced FEV1.  
In a Hungarian population of childhood asthma, 
rs6721961 T and rs2588882 G have been inversely 
correlated with the infection-induced asthma.  
Cardiovasular disorders  
The rs6721961 TT genotype has been associated 
with higher systolic and diastolic blood pressure in 
Japanese haemodialysis patients than the CC or CT 
genotypes.  
Similarly, haemodialysis patients with the 
rs35652124 TT genotype had higher diastolic blood 
pressure and higher cardiovascular mortality than 
CC or CT carriers.  
Finally, in a Netherlands population, it has been 
demonstrated that carriers of the rs2364723 (G/C) 
minor G allele showed lower triglyceride levels and 
reduced risk of cardiovascular mortality. 
Gastrointestinal disorders  
The rs6706649 C and rs35652124 C SNPs have 
higher frequency in Japanese patients with ulcerative 
colitis, and their presence has been correlated with a 
chronic continuous disease phenotype. In 
Helicobacter pylori-infected patients, the 
rs6706649C/rs35652124C and 
rs6706649C/rs35652124T haplotypes have been 
correlated with increased and decreased risk, 
respectively, of CpG methylation; 
rs6706649C/rs35652124T carriers with negative 
Helicobacter pylori test showed reduced risk of 
gastric cancer.  
Autoimmune disorders  
In a Mexican Mestizo population it was found that 
lupus nephritis in women was significantly 
associated with presence of the heterozygous 
rs35652124 (C/T).  
Breast cancer  
Homozygosity for rs6721961 (TT) or rs2706110 
(TT) has been associated with increased risk of 
breast cancer in a Finish population. Moreover, 
presence of the rs6721961 T allele together with the 
intronic rs1962142 A allele was associated with 
reduced Nrf2 expression in breast cancer tissue. In a 
study of a Finish population, Nrf2 rs2886182 (T/C) 
rare homozygous genotype TT has been significantly 
associated with poorer survival and recurrence-free 
survival in patients with breast cancer that had 
received adjuvant chemotherapy, and with poorer 
survival in patients with breast cancer that had 
undergone postoperative radiotherapy.  
Venous thromboembolism  
In postmenopausal women the rs6721961 (T allele) 
increased the risk of venous thromboembolism after 
oral estrogen therapy. 
Neurodegenerative diseases 
In Swedish populations, a protective effect against 
Parkinson's disease has been detected for a haplotype 
containing promoter SNPs rs7557529C/ 
rs35652124T/ rs6706649C/ rs6721961G as well as 
intronic SNPs rs2886161T/ rs1806649T/ 
rs2001350T/ rs10183914T) (Yamamoto et al., 2004; 
Marzec et al., 2007; Arisawa et al., 2008; Siedlinski 
et al., 2009; Masuko et al., 2011; Hartikainen et al., 
2012; Cho, 2013; Figarska et al., 2014; Shimoyama 
et al., 2014). 
* The nucleotides for each SNP correspond to the 
map on chr. 2, and are thus complementary to the 
gene sequence (NFE2L2 lies on the reverse strand). 










The dual role of Nrf2: NFE2L2 has been found to 
have both cancer chemopreventive activity (by 
protecting cells from carcinogen-induced damage 
and transformation) and oncogenic activity (by 
conferring a survival advantage to pre-malignant or 
malignant cells). Thus, on the one hand, activation of 
Nrf2 upregulates various conjugating enzymes for 
the detoxification of chemical carcinogens and 
protects from carcinogenicity, mutagenicity and 
other forms of toxicity. Experimental disruption of 
Nrf2 is associated with increased susceptibility of 
cells to carcinogens. The chemopreventive 
properties of Nrf2 have been demonstrated in several 
experimental models of cancer including colon, 
bladder, lung, stomach, breast, skin and liver cancer. 
Importantly, inducers of Nrf2 pathway are being 
tested in clinic trials for cancer chemoprevention. 
On the other hand, in various cancers Nrf2 protein 
abundance and activity have been found to be 
increased, suggesting a role in tumour growth and 
survival. Gain of function somatic mutations in 
NFE2L2 gene which lead to disruption of the Nrf2-
Keap1 binding interface complex result in 
upregulation of Nrf2 activity. These mutations have 
been identified in NSCLC, oesophageal squamous 
cell carcinoma, malignant melanoma, skin squamous 
cell carcinoma, head and neck carcinoma and 
cervical cancer. 
In addition, it has been reported that an indirect way 
of upregulation of Nrf2 activity is the loss of function 
KEAP1 somatic mutations. These mutations have 
been detected in various types of cancer [lung cancer 
(NSCLC), thyroid papillary cancer, oesophageal 
cancer, gastric adenocarcinoma, hepatocellular and 
cholangiocellular carcinoma, gallbladder cancer, 
colorectal adenocarcinoma, caecum carcinoma, 
breast ductal carcinoma and adenocarcinoma, 
endometrial adenocarcinoma, ovarian serous cancer 
and epithelial cancer, prostate adenocarcinoma, 
kidney and urinary tract cancer, malignant 
melanoma and neuroblastoma]. 
Another mechanism of constitutive activation of 
Nrf2 in cancer cells is the silence of KEAP1 gene 
caused by hypermethylation of KEAP1 gene 
promoter. This silencing mechanism of KEAP1 gene 
has been detected in human lung cancer tissue cells 
(squamous, adenocarcinoma,  
adenosquamous), lung cancer cell lines, human 
breast cancer tissues, colorectal cell lines, prostate 
cancer cell lines, human malignant gliomas and 
papillary thyroid cancer. Hypermethylation of CUL3 
and RBX1 genes as well as CUL3, RBX1 and 
KEAP1 copy number losses have been proposed as 
further Nrf2 activation mechanisms in papillary 
thyroid carcinoma. 
Moreover, Nrf2 expression and activation can be 
induced by Nrf2 cross-talk with other signalling 
pathways. Specifically, it has been demonstrated that 
in acute myeloid leukaemia (AML) Nrf2 
overexpression is driven by abnormal expression of 
Nuclear Factor-κB (NF-κB). In addition, in NSCLC 
cell lines constitutive activation of mutant epidermal 
growth factor receptor (EGFR) and RagD-mediated 
activation of mammalian target of rapamycin (m-
TOR) signalling pathway cause overactivation of 
Nrf2 as well as Nrf2-mediated resistance to EGFR-
tyrosine kinase inhibitor and m-TOR inhibitor, 
respectively. In renal cancer cells, Nrf2 activity has 
been found to be increased by downregulation of E-
cadherin which normally forms a quanternary 
complex with Nrf2, Keap1 and β-catenin and 
facilitates Keap1-mediated ubiquitination of Nrf2. 
Finally, it has been observed that transcriptional 
coactivator amplified in breast cancer 1 (AIB1) 
stimulates Nrf2 activation in cholangiocarcinoma 
cells inducing tumour proliferation and 
chemoresistance.  
Thus, AIB1 has been proposed as a Nrf2 coactivator. 
In summary, the upregulation of Nrf2 has 
antioxidant as well as cytoprotective effect in cancer 
cells. Especially, cytoprotective activity of Nrf2 can 
be exploited by cancer cells not only to face their 
oxidant tumour microenvironment, but also confer 
chemo- or/and radio- resistance during anticancer 
therapies. Consequently, suppression of Nrf2 
activity in cancer cells inhibits tumour growth and 
enhances the efficacy of chemotherapeutic agents. 
Therefore, Nrf2 could be a target not only for cancer 
chemoprevention (via activating compounds) but 
also for cancer treatment (via inhibitors) (Shibata et 
al., 2008a; Shibata T. et al, 2008b; Wang et al., 2008; 
Chen et al., 2010; Solis et al., 2010; Yoo et al., 2010; 
Kim et al., 2010; Shibata et al., 2010; Wang et al., 
2010; Muscarella et al., 2011; Shibata et al., 2011; 
Chen Q et al., 2012; Guo et al., 2012; Hanada et al., 
2012; Hu et al., 2012; Kim et al., 2012; Liao et al., 
2012; Sporn and Liby, 2012; Yamadori et al., 2012; 
Barbano et al., 2013; Ga&ntildeán-Gómez et al., 
2013; Martinez et al., 2013; Shelton and Jaiswal, 
2013; Shin et al., 2013; Ziros et al., 2013; Zhang et 
al., 2013; Funes et al., 2014; Gorrini et al., 2014; Ji 
et al., 2014; Onodera et al., 2014; Schultz et al., 
2014). 
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Exogenous Nrf2 inducers. 
 
Disease 
Lung cancer, thyroid cancer, ovarian cancer, breast 
cancer, prostate cancer, endometrial cancer, cervical 
cancer, gastric cancer, oesophagus cancer, colorectal 
cancer, gallbladder cancer, liver cancer, skin cancer, 
acute myeloid leukemia. 
Airway diseases 
Oxidative stress has been associated with the 
pathogenesis of many acute and chronic airway 
disorders.  
ALI and its severe form ARDS are characterised by 
severe systemic hypoxemia in seriously ill patients. 
Hypoxemia is associated with production of 
excessive ROS, and thus oxidative stress is a major 
contributor to the pathogenesis of ALI. In such 
hypoxic situations oxygen is one of the most 
commonly used supplemental therapeutic agents. 
However, oxygen supplementation-induced 
hyperoxia can also cause lung injury and airway 
inflammation. Nrf2 has been proposed as a 
hyperoxia susceptibility gene that modulates ALI in 
vivo.  
Emphysema is characterised by loss of pulmonary 
elasticity as a result of permanent alveolar wall 
destruction and represents the alveolar lesion in 
COPD. Cigarette smoke is a major contributor to 
emphysema and COPD pathogenesis. Chronic 
exposure to cigarette smoke in Nrf2 knockout (KO) 
mice causes more severe emphysema than in wild 
type mice. This is associated with greater levels of 
inflammation, oxidative stress and endothelial and 
epithelial cell apoptosis in the Nrf2 KO mice.  
LPS (lipo-polysaccharide)-induced septic shock in 
Nrf2 KO mice results in premature mortality in 
comparison with wild type mice, and non-lethal 
exposure to LPS results in greater lung inflammation 
and injury in Nrf2 KO mice.  
Regarding asthma disease, it has been observed that 
the disruption of Nrf2 can cause severe airway 
inflammation and airway hyper-responsiveness in 
mouse models of asthma. 
IPF is a fibroproliferative disease thought to be 
triggered by repeated alveolar epithelial cell injury. 
Rodent models of bleomycin-induced lung fibrosis 
have been used to study IPF. The pulmonary 
fibrogenic effects of bleomycin are antagonised by 
antioxidant enzymes like SODs in rodents. 
Moreover, it has been noticed that Nrf2 KO mice 
treated with bleomycin had elevated levels of TGF-
β, the main fibrogenic factor. 
Finally, it has been reported that Nrf2 has a 
protective role against airway infection by RSV in 
mice (Reddy, 2008; Cho and Kleeberger, 2010). 
Disease 
Acute lung injury (ALI), emphysema/chronic 
obstructive pulmonary disease (COPD), lung 
disorder during sepsis [LPS (lipo-polysaccharide)-
induced septic shock], asthma/allergic airway 
diseases, idiopathic pulmonary fibrosis (IPF), viral 
airway disease (RSV - respiratory syncytial virus) 
Cardiovascular disease 
Nrf2 is expressed in the cardiovascular system (heart 
and blood vessels), and Nrf2 signaling is implicated 
in the regulation of vascular homeostasis and in the 
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prevention of cardiac hypertrophy and heart failure 
via suppression of oxidative stress. Although Nrf2 
has been proposed as a therapeutic target in 
cardiovascular diseases like atherosclerosis, there is 
some evidence that reveal the role of Nrf2 as pro-
atherogenic factor via a different mechanism. 
Nevertheless, modulation of Nrf2 has been 
supported for the prevention and the treatment of 
heart diseases (Sussan et al., 2008; Koenitzer and 
Freeman, 2010; Freigang et al., 2011). 
Diabetes, diabetic nephropathy, 
diabetic neuropathy 
Nrf2-mediated expression of endogenous 
cytoprotective enzymes and other antioxidant 
molecules has been shown to be an adaptive defence 
mechanism against high glucose-induced oxidative 
damage in diabetes. Diabetic nephropathy and 
neuropathy have been studied in correlation with the 
activity of Nrf2 pathway, and it has been found that 
Nrf2 exerts a protective role against these long-term 
complications of diabetes (Jiang et al., 2010; Cheng 
et al., 2011; Negi et al., 2011). 
Obesity/metabolic syndrome 
While it appears that the Nrf2 pathway is a regulator 
of energy metabolism, its precise effects and the 
underlying mechanisms are still controversial. In 
some contexts Nrf2 is protective and high-fat diet-
induced obesity, while in others it is a contributing 
factor to metabolic disease. Nrf2 can induce several 
metabolic regulators in adipose tissue and liver such 
as PPARγ, C/EBPβ and AhR, and it can repress 
others such as FGF21. The exact mechanisms by 
which Nrf2 cross-talks with these factors are the 
focus of ongoing research (Chartoumpekis and 
Kensler, 2013). 
Liver and gastrointestinal diseases 
Nrf2 has been demonstrated to be a key factor 
dictating susceptibility to oxidative and chemical-
induced injury in the gastrointestinal system. In vivo 
experiments have revealed that Nrf2 KO mice are 
more susceptible to acetaminophen-induced 
hepatocellular injury, benzo(a)pyrene-induced 
tumour formation, and Fas- and TNFα-mediated 
hepatocellular apoptosis. In addition, Nrf2 may be 
important in protecting against liver fibrosis and 
gallstone development. Regarding intestinal 
diseases, it has been suggested that Nrf2 plays an 
important role in the maintenance of intestinal 
integrity and may serve as novel target for therapies 
to prevent or treat Crohn's disease or ulcerative 
colitis (Aleksunes and Manautou, 2007). 
Disease 
Drug-induced hepatotoxicity, hepatocellular 
apoptosis, liver fibrosis, gallstone disease, bowel  
diseases (Crohn's disease and ulcerative colitis), 
chemical carcinogenesis in the gastrointestinal 
system 
Neurodegenerative diseases 
Oxidative stress is involved in the pathogenesis of a 
wide range of chronic neurodegenerative diseases 
such as AD, PD and HD.  
AD is characterised by increased accumulation in the 
brain of neurotoxic and oxidative elements such as 
iron. In addition, increased oxidative damage of 
proteins and lipid peroxidation has been detected in 
the brain of AD patients. Reactive astrocytes and 
activated microglia contribute to the oxidative stress 
observed in AD brain. The expression profile of Nrf2 
and ARE-regulated proteins in AD brain tissue 
supports the hypothesis that Nrf2 signalling may be 
involved in the early stages of AD. 
PD, the second most common neurodegenerative 
disease after AD, is characterised by the preferential 
loss of dopaminergic neurons in the substantia nigra. 
Mitochondrial dysfunction and neuroinflammation 
in PD play a crucial role in PD pathogenesis and the 
subsequent oxidative stress has been suggested to be 
responsible for the degeneration of nigral 
dopaminergic neurons. Nrf2 pathway may have a 
neuroprotective effect on PD and its activation may 
be a novel therapeutic approach. 
HD is a rare neurodegenerative disorder inherited in 
an autosomal dominant manner. Work in mouse 
model has shown that Nrf2 can have neuroprotective 
roles against HD and might be a novel treatment 
target for HD. Furthermore, it has been reported that 
Nrf2 can also potentially protect from neuronal 
damage in other neurological diseases such as ALS, 
Freidrich's ataxia, Down syndrome, multiple 
sclerosis, traumatic brain injury and cerebral 
haemorrhages (Ramsey et al., 2007; Calabrese et al., 
2008; de Vries et al., 2008; Jazwa et al., 2011; 
Tufekci et al., 2011). 
Disease 
Alzheimer's disease (AD), Parkinson's disease (PD), 
Huntington's disease(HD), Freidrich's ataxia, 
amyotrophic lateral sclerosis (ALS), multiple 
sclerosis, Down syndrome, traumatic brain injury, 
cerebral haemorrhage 
Rheumatoid arthritis 
ROS play an important role in the pathogenesis of 
rheumatoid arthritis (RA), and antioxidant 
substances and enzymes reduce cartilage damage in 
animal models of RA. It has been reported that a 
deficiency in Nrf2-mediated antioxidant defences 
plays a central role in pathogenesis of RA. Oxidative 
stress is one of the factors that contribute to RA, and 
Nrf2 could play an important role in alleviating its 
effects (Wruck et al., 2011). 
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Uveitis 
Uveitis is an inflammatory eye disease that can cause 
blindness.  
The main characteristic of uveitis is an inappropriate 
innate immune response resulting in local tissue 
injury.  
ROS production with secretion of inflammatory 
cytokines and leukocytes infiltration has been 
documented in a model of LPS-induced uveitis.  
In this model, due to an inadequate activation of 
Nrf2, the induction of antioxidant and anti-
inflammatory responses is also incomplete. 
Potentiation of the antioxidant response with an 
Nrf2-inducing compound led to increased enzyme 
expression of protective enzymes, reduced cytokine 
expression, and decreased leukocyte adhension, 
suggesting Nrf2 as a potential therapeutic target in 
uveitis (Nagai, 2009). 
Aging 
A popular "hypothesis" about the causes of aging is 
the "free radical theory", which considers aging as 
the result of progressive damage to macromolecules 
and cellular structures caused by exposure to 
endogenous and exogenous pro-oxidant substances, 
notably free radicals. Nrf2 and its homologues in 
invertebrate models of aging have been shown to 
exert anti-aging and pro-longevity functions. 
Nevertheless, Nrf2 activity generally declines with 
age, and this decline is associated with decreased 
expression and/or inducibility of antioxidant genes. 
Overall, it is believed that, if properly fine-tuned, the 
Nrf2 pathway can have life span-extending effects, 
and can therefore be a target for promoting longevity 
and extending the disease-free period of life (the 
"health span") (Sykiotis and Bohmann, 2010). 
 
Genes positively regulated by Nrf2 in humans. 
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